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• Pulmonary Embolism (PE) affects more than 900,000 Americans 
annually with an estimated 60,000 – 100,000 deaths per year and an 
estimated one-month mortality rate of 10%-30%1.
• According to the American Heart Association (AHA), risk stratification of 
PE’s is categorized as either massive (MPE), submassive (SPE), or 
non-massive based on various hemodynamic and clinical factors. 
• The Emergency Department (ED) is often utilized for management and 
subsequent prevention of further adverse outcomes of PE, but 
diagnostic and therapeutic challenges arise due to variability in 
presentation and response to treatment. 
• The Pulmonary Embolism Severity Index (PESI) is a composite metric 
that can also be used to determine prognosis of PE in the ED as a 30-
day outcome, informing treatment options through a 5-point scale.
• AHA supports Catheter-Directed Thrombolysis (CDT) or Systemic 
Thrombolysis (ST) involving alteplase administration for management of 
an MPE, which has been shown to raise the risk of adverse outcomes 
post intervention with no standard of care recommended for SPE. 
• These outcomes and uncertainties make it imperative to determine the 
benefits and adverse outcomes associated with either treatment for 
both MPE and SPE while also seeing if existing tools can be used as a 
clinical decision tool for ED physicians.
• The objective of this study is to analyze CDT or ST/no treatment for 
outcomes and investigate PESI profiles for each treatment among for 
MPE and SPE patients. This analysis can inform ED management and 
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• In this retrospective study, data was obtained via 2 methods
• Inclusion criteria: Patient > 18 years of age presenting with an MPE or 
SPE and received treatment based on their group
• Both prisoners and pregnant patients were excluded from this study
• EMR data was reviewed twice by different teams across all metrics 
collected including demographics, vital signs, medical history, serum 
biomarkers (e.g. troponin and NT-proBNP) and echocardiography.
• PESI was spit into low risk (tiers 1,2) and high-risk (tiers 3,4,5,).
First data set was gathered 
from prospectively from 
patients presenting with either 
a MPE or an SPE who were 
treated with CDT (defined as 
cases): N = 432
Second data set was collected 
retrospectively from patients 
presenting with MPE or SPE who 
were treated with a systemic 
thrombolytic or anti-coagulant only 
(defined as controls): N = 611
A propensity score match method was 
used for standardization that included 
race, age, BMI, Gender, PESI Risk, 
diagnosis of a Massive vs. 
Submassive PE
N = 336
Cases: N = 168 Controls: N = 168
• Comparators were defined and logistics regressions + Chi-Squared 
analysis were done between metrics and comparators using SPSS.
Table 1: Defining Outcomes and Analyzing Against Variables To Determine 
Subpopulations with Adverse or Positive Outcomes With Each Treatment Modality 
Outcome Category of Variables Hypothesized to be 
Correlated with All Outcome Between 
Both Treatments
Negative Outcomes ● Demographic Hospital Index
● Pulmonary Embolism Severity Index 
(PESI)
● Inpatient Procedures and Medication
● Biomarkers (e.g. Troponin and Brain 
Natriuretic Peptide)
● History of PE or DVT
● Anticoagulant use
● Presence of Hypertension
● Length of Stay





Decrease in RV Hypokinesis between 
baseline and post CDT echo (Attribute of 
RV Dysfunction)
Table 2: Value of Variables Post Propensity Score Match Between the Cases and 
Control Groups
Variable Name Value Among 
Both Groups: 
N = 336 (%)
Cases: N = 168 
(%)






224 (66.7) 107 (63.7) 117 (69.6) 0.247




Male 163 (48.5) 79 (47.0) 84 (50.0) 0.585
Female 173 (51.5) 89 (53.0) 84 (50.0)
PESI
Low Risk (1-2) 96 (28.6) 46 (27.4) 50 (29.4) 0.629
High Risk (3-5) 240 (71.4) 122 (72.6) 118 (70.2)
PE Status
Massive 208 (61.9) 102 (60.7) 106 (63.1) 0.653
Submassive 128 (38.1) 66 (39.3) 62 (36.9)
Table 3: Analysis of Comparators Against Each Treatment Modality
Variable Total: N = 
336 (%)




Present 40 (11.9) 13 (18.5) 9 (5.4) 0.0003
Not Present 296 (88.1) 137 (81.6) 159 (94.6)
Mortality
Yes 20 (6.0) 9 (5.4) 11 (6.5) 0.645
No 316 (94.0) 159 (94.6) 157 (93.5)
Right Ventricular Dilation 
Yes 130 (38.7) 46 (35.4) at admission 
to 46 (35.4) 
post-procedure
10 (7.7) at admission 




Decrease in RV Hypokinesis Between Baseline and Post- CDT
Yes 93 (27.7) 43 (46.2) at admission 
to 34 (36.6) 
post-procedure





Table 5: Multiple Logistic Regression Analysis Between Comparators and 
Hypothesized Correlates Associated with Positive or Adverse Outcomes in CDT 
Patients (N = 186)
Comparator Hypothesized Correlate (In 
Both MPE and SPE) from 
patients who underwent 
CDT
p (2-tailed)
Mortality Elevated Brain Natriuretic 
Peptide (BNP)
0.015
History of Deep Vein 
Thrombosis (DVT)
0.043
History of Aspirin Use 0.012
Bleeding Complications Length of Hospitalizations 0.015
Decrease in RV 
Hypokinesis Between 
Baseline and Post-CDT 
Echo
No correlates were significant or close to 
being significant
• This study does not show conclusively whether CDT or ST/no were 
more effective than the other but, does show a significant increase in 
bleeding complications among those who underwent CDT.
• Regardless of PESI score, it could be seen that CDT intervention was 
associated with a greater incidence in complications as well as a longer 
length of hospital stay.
• Further studies need to be done to stratify and identify those patients 
who would truly benefit from CDT both among the MPE and SPE 
groups.
• While the integrity of the propensity matching was determined to be 
viable, it can be strengthened by controlling for more variables.
• Define further comparators to strengthen comparison as well as 
produce a nuanced analysis on hypothesized outcomes to determine 
further characteristics that can influence adverse or positive outcomes 
among SPE and MPE patients.
• Use this analysis to develop a novel decision-making algorithm for ED 
physicians to efficiently administer treatment for better prognosis while 
also saving crucial time.
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Low risk PESI: N = 96 & High Risk PESI: N = 240
Table 4: Investigation of PESI Against Comparators
Comparators PESI Category Cases (%) Control (%) P (2-tailed)
Mortality Low Risk (N=96) 2 (2.1) 0 (0.0) 0.170
High Risk (N=240) 9 (3.8) 9 (3.8) 0.941
Bleeding 
Complications
Low Risk (N=96) 10 (10.4) 0 (0.0) 0.001
High Risk (N=240) 21 (8.8) 9 (3.8) 0.015
Length of Stay
(Days)
Low Risk (N=96) 5.5 (5.7) 3.8 (4.0) 0.013
High Risk (N=240) 9.4 (3.9) 6.9 (2.9) 0.005
